IPP Bureau
LogiPharma launches Asian focused summit, coming to Singapore in June 2023
By IPP Bureau - April 05, 2023
The summit encompasses multiple verticals, spanning from pharmaceuticals, biotech, life sciences, and the Healthcare sector to ensure an unbiased and comprehensive view on the future of the function.
Dozee Raises $6 million to bolster its ambition of ‘HarBedDozeeBed’
By IPP Bureau - April 05, 2023
Dozee plans to further tap over 2,000 hospitals in more than 100 districts
Israeli researchers develop an effective drug to prevent muscle diseases
By IPP Bureau - April 05, 2023
The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.
FDA approves Merck’s Keytruda in combination with Padcev for treatment of metastatic urothelial cancer
By IPP Bureau - April 04, 2023
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
Biocon awarded Silver Medal by EcoVadis for sustainability accomplishments
By IPP Bureau - April 04, 2023
For the year 2022, Biocon bettered its score in all the four EcoVadis themes – Environment (70), Labor & Human Rights (70), Ethics (60), and Sustainable Procurement (60)
Top management changes at IOL Chemicals and Pharmaceuticals
By IPP Bureau - April 04, 2023
Vikas Vij has been appointed as Chief Executive Officer (CEO) of the company
Antibody-drug conjugates gain traction in China oncology market, says GlobalData
By IPP Bureau - April 04, 2023
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
TSCS team met All India Imam Organization Chief to discuss on thalassemia eradication in India
By IPP Bureau - April 04, 2023
Chief Imam of All India Imam Organization, Dr. Imam Umer Ahmed Ilyas, evinces keen interest in the eradication of Thalassemia & Sickle Cell Disease
CBC Group appoints Abbas Hussain as Operating Partner
By IPP Bureau - April 03, 2023
Abbas will closely partner with CBC's business teams to identify, assess, and pursue investment opportunities and strategic acquisitions
GSK and SCYNEXIS announce agreement to commercialise and further develop Brexafemme
By IPP Bureau - April 03, 2023
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
EIP Pharma and Diffusion Pharmaceuticals inks agreement to create CNS-focused company
By IPP Bureau - April 03, 2023
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
Immutep announces expansion of triple combination therapy in first-line non-small cell lung cancer
By IPP Bureau - April 03, 2023
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
Hutchmed completes rolling submission of NDA to USFDA for fruquintinib
By IPP Bureau - April 03, 2023
NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
Apollo Cancer Centres, Navi Mumbai launches 4th gen Da Vinci Xi Robotic Surgical System
By IPP Bureau - April 01, 2023
Launch of the Da Vinci Xi Robotic System is the highlight of the Robotic Colorectal Cancer Symposium organized with the Association of Colon and Rectal Surgeons of India
Alniche Lifesciences expands footprints in respiratory care
By IPP Bureau - April 01, 2023
The upcoming portfolio of respiratory products aims to provide effective solutions for a range of respiratory conditions
